N@N

Terence Flynn Maintained (ABBV) at Buy with Increased Target to $182 on, Apr 28th, 2023

Terence Flynn of Morgan Stanley, Maintained "AbbVie Inc." (ABBV) at Buy with Increased Target from $181 to $182 on, Apr 28th, 2023.

Terence has made no other calls on ABBV in the last 4 months.

There are 10 other peers that have a rating on ABBV. Out of the 10 peers that are also analyzing ABBV, 6 agree with Terence's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Carter Gould of "Barclays" Maintained at Hold with Increased Target to $160 on, Thursday, April 13th, 2023
• Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Wednesday, April 5th, 2023
• Tim Anderson of "Wolfe Research" Downgraded from Buy to Hold on, Wednesday, February 22nd, 2023
• Navin Jacob of "UBS" Maintained at Hold with Increased Target to $152 on, Friday, February 10th, 2023
• Steve Chesney of "Atlantic Equities" Maintained at Hold with Decreased Target to $154 on, Friday, February 10th, 2023
• David Risinger of "SVB Leerink" Upgraded from Sell to Hold and Increased Target to $153 on, Friday, February 10th, 2023

These are the ratings of the 4 analyists that currently disagree with Terence

---

• Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $163 on, Friday, February 10th, 2023
• Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Buy with Increased Target to $165 on, Thursday, February 9th, 2023
• Robyn Karnauskas of "Truist Securities" Reiterated at Strong Buy and Held Target at $180 on, Thursday, February 9th, 2023
• Gary Nachman of "BMO Capital" Maintained at Buy with Decreased Target to $167 on, Monday, February 6th, 2023

Contributing Sources

---